Abstract
Background Clinical studies have found comorbidity between Inflammatory Bowel Disease (IBD) and primary sclerosing cholangitis (PSC). Primary biliary cholangitis (PBC) is another autoimmune liver disease but the coexistence of IBD and PBC is rare. Whether there exists comorbidity between IBD and PBC and potential mechanism remains unclear.
Methods We assessed the casual effect between PBC and IBD, i.e., Crohn Disease (CD) and Ulcerative Colitis (UC) independently based on genome-wide association studies (GWAS) summary statistics. By leveraging data from GWAS data, Bulk tissue RNA sequencing (bulk RNA-seq) data, and Single-cell RNA sequencing (scRNA-seq) dataset, we investigated the shared genetic architecture between IBDs and PBC. The transcriptomic expressions of shared genes were explored in patients with IBD (intestinal biopsies) and PBC (peripheral CD4+ T cells).
Result We found a bidirectional causal relationship for PBC and IBDs using Mendelian randomization. The IBDs had been considered as the protective factors on PBC (0.87[95% confidence interval (CI): 0.81-0.93], P = 8.72e-5, vice versa (0.91[95% CI: 0.81-0.93], P = 2.65e-09). We find a consistent negative genetic correlation between PBC and IBD (LDSC: rg = -0.2245, P = 2.89e-5). Cross-trait analysis yielded 9 shared risk SNPs and 7 nearest genes. In transcriptome analysis, we observed significant (P < 0.05) differences expression in intestinal biopsies (PGAP3 and DENND1B) and in peripheral CD4+ T cells (PTPN11 and PNMT). We identified shared tissue-specific heritability enrichment for PBC and IBD (including CD not UC) in lung, spleen and cells EBV-transformed lymphocytes and identified shared cell type-level enrichment for IBD, CD and PBC in type 1 dendritic cells, natural killer cells, CD8+ cytotoxic T lymphocytes in lung and activated CD8+ T cell in spleen.
Conclusion Our study indicates that IBD and PBC are protective factors for each other and shared genetic architecture may contribute to the negative genetic correlation. These findings may explain the rare comorbidity between IBD and PBC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Natural Science Foundation of China (82171698, 82170561, 81300279, and 81741067), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), Natural Science Foundation of Guangdong Province (2022A1515012081), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201803, KJ012019099, KJ012021143, and KY012021183).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GWAS summary statistics for PBC are available by application from: https://www.ebi.ac.uk/gwas/. GWAS summary statistics for PBC for replication are available by application from: https://gwas.mrcieu.ac.uk/. GWAS summary statistics for IBD are available by application from: https://www.ebi.ac.uk/gwas/. GEO dataset: PBC: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi IBD: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179285 GTEx-seq: https://alkesgroup.broadinstitute.org/LDSCORE/LDSC_SEG_ldscores scRNA-seq data: Whole blood: Lung and Spleen: https://doi.org/10.1186/s13059-019-1906-x; Small Intestinal Epithelium: https://singlecell.broadinstitute.org/single_cell/study/SCP44/small-intestinal-epithelium
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at
